6533b832fe1ef96bd129ae5b
RESEARCH PRODUCT
Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: A pharmacogenomic approach.
Maria Paola GrimaldiFlorinda ListìMartina ChiappelliMartina ChiappelliGiuseppina Colonna-romanoFederico LicastroCarmela Rita BalistreriCalogero CarusoDomenico LioSonya VastoGiuseppina Candoresubject
RiskAgingDiseaseBiologyBioinformaticsPathogenesisDegenerative diseaseGeneticAlzheimer DiseaseGenetic variationmedicineDementiaSettore MED/05 - Patologia ClinicaAnimalsHumansGeneGeneticsInflammationSettore MED/04 - Patologia GeneraleGenomePolymorphism Geneticmedicine.diseasePharmacogeneticsPharmacogenomicsAlzheimer's diseaseInflammation MediatorsPharmacogenomicsAlzheimer’s diseaseDevelopmental Biologydescription
Clinically and pathologically Alzheimer's disease (AD) represents a sequential progressive neurodegenerative disorder. AD is etiologically heterogeneous and accounts for a majority of dementia in western societies. Inflammation clearly occurs in pathologically vulnerable regions of the AD brain and the search for genetic factors influencing the pathogenesis of AD has lead to the identification of numerous gene polymorphisms that might act as susceptibility modifiers. Accordingly, several reports have indicated that the risk of AD is substantially influenced by several genetic polymorphisms in the promoter region, or other untranslated regions, of genes encoding inflammatory mediators, although not all the studies were replied. Here, we review several data suggesting that inflammatory genetic variation may contribute to AD susceptibility. All together this information may represent the basis both for future recognition of individuals at risk and for the pharmacogenomic driving of drug responsiveness.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2006-11-23 |